Open AccessRole of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting
Author(s) -
Xu Maosen,
Wang Yang,
Xia Ruolan,
Wei Yuquan,
Wei Xiawei
Publication year - 2021
Publication title -
cell proliferation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.647
H-Index - 74
eISSN - 1365-2184
pISSN - 0960-7722
DOI - 10.1111/cpr.13115
Subject(s) - ccr2 , ccl2 , cancer research , cancer , chemokine , biology , tumor microenvironment , medicine , chemokine receptor , immunology , tumor cells , inflammation , genetics
The chemokine ligand CCL2 and its receptor CCR2 are implicated in the initiation and progression of various cancers. CCL2 can activate tumour cell growth and proliferation through a variety of mechanisms. By interacting with CCR2, CCL2 promotes cancer cell migration and recruits immunosuppressive cells to the tumour microenvironment, favouring cancer development. Over the last several decades, a series of studies have been conducted to explore the CCL2‐CCR2 signalling axis function in malignancies. Therapeutic strategies targeting the CCL2‐ CCR2 axis have also shown promising effects, enriching our approaches for fighting against cancer. In this review, we summarize the role of the CCL2‐CCR2 signalling axis in tumorigenesis and highlight recent studies on CCL2‐CCR2 targeted therapy, focusing on preclinical studies and clinical trials.